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We previously reported a granulin (GRN) null mutation, originating from a common founder, in multiple
Belgian families with frontotemporal dementia. Here, we used data of a 10-year follow-up study to describe
in detail the clinical heterogeneity observed in this extended founder pedigree. We identiﬁed 85 patients
and 40 unaffected mutation carriers, belonging to 29 branches of the founder pedigree. Most patients
(74.4%) were diagnosed with frontotemporal dementia, while others had a clinical diagnosis of unspeciﬁed
dementia, Alzheimer’s dementia or Parkinson’s disease. The observed clinical heterogeneity can guide
clinical diagnosis, genetic testing, and counseling of mutation carriers. Onset of initial symptomatology is
highly variable, ranging from age 45 to 80 years. Analysis of known modiﬁers, suggested effects of GRN
rs5848, microtubule-associated protein tau H1/H2, and chromosome 9 open reading frame 72 G4C2 repeat
length on onset age but explained only a minor fraction of the variability. Contrary, the extended GRN
founder family is a valuable source for identifying other onset age modiﬁers based on exome or genome
sequences. These modiﬁers might be interesting targets for developing disease-modifying therapies.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Frontotemporal lobar degeneration (FTLD) is a heterogeneous
group of neurodegenerative disorders. Three clinical subtypes have
been deﬁned: the behavioral variant of frontotemporal dementiagy (BELNEU) Consortium.
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Inc. This is an open access article u(bvFTD) and the nonﬂuent and semantic variant of primary pro-
gressive aphasia (PPA) (Gorno-Tempini et al., 2011; Rascovsky et al.,
2011). The pathological hallmark of FTLD is neuronal loss in the
frontal and temporal lobes of the brain (Neary et al., 2005). FTLD is a
proteinopathy and, based on the nature of the inclusion proteins, 5E-mail address: christine.vanbroeckhoven@molgen.vib-ua.be (C. Van Broeckhoven).
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microtubule-associated protein tau (MAPT), and FTLD-Tat activating
regulatory (TAR)DNA-binding protein (FTLD-TDP) are the most
frequent pathological diagnoses (Mackenzie and Neumann, 2016).
Causal mutations have been identiﬁed in 6 genes, namely granulin
(GRN), chromosome 9 open reading frame 72 (C9orf72), MAPT,
TANK-binding kinase 1 (TBK1), valosin-containing protein (VCP),
and charged multivesicular body protein 2B (CHMP2B) (Baker et al.,
2006; Cruts et al., 2006; Dejesus-Hernandez et al., 2011; Freisch-
midt et al., 2015; Gijselinck et al., 2012, 2015; Hutton et al., 1998;
Poorkaj et al., 1998; Pottier et al., 2015; Renton et al., 2011; Skibinski
et al., 2005; Spillantini et al., 1998; Watts et al., 2004). Variations in
these genes have been suggested to modify disease risk, such as the
common variation rs5848 in GRN, the H1/H2 haplotype of MAPT,
and intermediate alleles of 7e24 repeat units of the C9orf72 G4C2
repeat (e.g., [Benussi et al., 2014; Borroni et al., 2005; Gijselinck
et al., 2012; Rademakers et al., 2008; Verpillat et al., 2002]). In
addition, a genome-wide association study identiﬁed variations in
TMEM106B as risk factors for FTLD-TDP (Van Deerlin et al., 2010).
GRN mutations explain 10%e25% of all and 3%e26% of familial
FTD patients (http://www.molgen.vib-ua.be/FTDMutations; Cruts
et al., 2012; Sieben et al., 2012). The majority are heterozygous
loss-of-function mutations that lead to premature stop codons trig-
gering degradation of the mutant transcript. Consequently, reduced
GRN levels are measured in blood and cerebrospinal ﬂuid (CSF)
(Finch et al., 2009; Ghidoni et al., 2008; Sleegers et al., 2009). In brain,
FTLD-TDP pathology type A is typically present (Mackenzie and
Neumann, 2016). Clinical phenotypes are diverse, even between
patients carrying the same mutation, and include FTD, Alzheimer’s
dementia (AD), Parkinson’s disease (PD), and corticobasal syndrome
(e.g., [Brouwers et al., 2007; Kelley et al., 2009]). Mutation carriers
show a high interfamilial and intrafamilial variability in onset age
ranging from 35 to 89 years (Cruts and Van Broeckhoven, 2008; Cruts
et al., 2012; Van Swieten and Heutink, 2008). This suggests that
modiﬁers inﬂuence the disease onset and clinical appearance. Vari-
ations near sortilin (SORT1), a receptor of GRN, and prosaposin (PSAP)
regulate GRN levels, but their effect on clinical heterogeneity remains
unclear (Carrasquillo et al., 2010; Nicholson et al., 2016).
We identiﬁed in an extended Belgian FTD family a GRN founder
mutation in the splice donor site of intron 1 (mutation alias
IVS1þ5 G>C, protein p.0). The mutation prevents splicing of intron
1, leading to nuclear retention and degradation of the mutant
transcript, which results in haploinsufﬁciency (Cruts et al., 2006).
Since its identiﬁcation, the pedigree has been extended and addi-
tional genealogical and clinical data have been gathered. The
Belgian GRN founder mutation is one of the most common GRN
mutations worldwide, in addition to the p.Arg493X mutation
(Rademakers et al., 2007) and the p.Thr272SerfsX10 mutation,
which is the most frequent GRN mutation in Italy (Benussi et al.,
2009, 2010; Borroni et al., 2011b). For all 3 mutations, founder ef-
fects have been described (Benussi et al., 2013; Borroni et al., 2011a;
Cruts et al., 2006; Rademakers et al., 2007; van der Zee et al., 2006).
The 10-year follow-up study of the Belgian GRN founder pedigree
allowed us to describe in detail the clinical heterogeneity of the GRN
patient carriers. The observed heterogeneity in onset age and the
size of the extended pedigree provided an opportunity to investi-
gate the potential onset age-modifying effects of known genetic
modiﬁers of FTD risk or disease presentation.
2. Materials and methods
2.1. Study population
Index patients were ascertained in Belgium through an
ongoing multicenter collaboration of neurology departments andmemory clinics partnering in the BELNEU consortium. Additional
patients, referred to the diagnostic service facility for genetic
testing, were included. Information on family history of neuro-
degenerative diseases was gathered for the index patients, and
relatives were asked to participate in genetic studies. Written
informed consent for participation in clinical and genetic studies,
and for the brain autopsy when appropriate, was obtained from
participants and/or their legal guardians. The clinical study pro-
tocol and the informed consent forms for patient ascertainment
were approved by the local ethics committees of each of the
collaborating neurological centers. The genetic and pathological
study protocols and informed consent forms were approved by the
ethics committee of the University Hospital of Antwerp and the
University of Antwerp, Belgium.
FTD, AD, or PD diagnoses were made in accordance with the
international consensus criteria (Gelb et al., 1999; Gorno-Tempini
et al., 2011; McKhann et al., 1984, 2011; Postuma et al., 2015; Ras-
covsky et al., 2011). Patients with a combination of behavioral and
language features of FTD at presentation, without clear predomi-
nance, were denoted mixed FTD. In addition to index patients,
symptomatic relatives with a clinical diagnosis carrying the founder
mutation were included in the clinical study. All available clinical
records were reviewed by a medical doctor of the research team
(Sara Van Mossevelde). A positive familial history was deﬁned as
the presence of at least 1 ﬁrst degree or 2 second degree relatives
with neurodegenerative disease. The onset age was deﬁned as the
age at which ﬁrst symptoms were noticed by the patient or his
partner/relatives. Supplementary Fig. S1 summarizes the available
biomaterials and clinical information.
2.2. Genetic screening
2.2.1. Targeted resequencing of genes involved in neurodegeneration
GRN founder mutation carriers and their family members
were screened for mutations using parallel screening of a mul-
tigene panel of neurodegenerative brain disease-related genes
(Agilent, https://www.agilent.com). Multiplex polymerase chain
reactions (PCR) were performed for target enrichment of the
coding regions of 17 causal genes and the apolipoprotein E gene
(APOE). This was followed by equimolar pooling of the amplicon
libraries and puriﬁcation using Agencourt AMPureXP beads
(Beckman Coulter). A universal PCR was performed to incorpo-
rate patient-speciﬁc barcodes. Samples were pooled, and massive
parallel sequencing was performed in-house on an Illumina
MiSeq platform. Paired-end reads were generated, and adapters
were trimmed using Fastq-mcf. Reads were aligned to the refer-
ence genome hg19 with the Burrows-Wheeler Aligner
MEMv0.7.5a (Li and Durbin, 2009). Variant calling and annotation
was performed using GATKv2.4 UniﬁedGenotyper and the
GenomeComb package (McKenna et al., 2010; Reumers et al.,
2012). We focused on known pathogenic mutations present
within the genes amyloid beta precursor protein, presenilin 1,
presenilin 2, GRN, MAPT, TBK1, CHMP2B, VCP, superoxide
dismutase 1, TAR DNA-binding protein (TARDBP), FUS RNA
binding protein FUS, prion protein, synuclein alpha, leucine rich
repeat kinase 2, parkin RBR E3 ubiquitin protein ligase (PARKN),
parkinsonism associated deglycase (PARK7), and PTEN induced
putative kinase 1. We have identiﬁed 2 carriers of the p.G287S
mutation in the TARDBP gene in branch DR404 of the founder
pedigree (Table 1, Supplementary Fig. S2). Individual III.3 car-
ried both mutations and was unaffected at 65 years. Sibling III.5
carried only the TARDBPmutation and was unaffected at 57 years.
According to relatives, the parent II.3 showed a reduction in
speech at 80 years, mutism at age 84 years, and loss of interest in
the surroundings at 85 years. The spouse of II.3 died unaffected at
E. Wauters et al. / Neurobiology of Aging 67 (2018) 84e948680 years. The p.G287S mutation has been identiﬁed in patients
suffering from amyotrophic lateral sclerosis (Corrado et al., 2009;
Kabashi et al., 2008; Kenna et al., 2013; Kirby et al., 2010).
2.2.2. Screening of candidate onset age modiﬁer variations
The gene panel of neurodegenerative brain disease-related
genes also targets regions encompassing candidate modiﬁer var-
iations, that is rs429358 and rs7412 for APOE genotyping, the GRN
30-untranslated region (UTR) variant rs5848, and MAPT rs1052553
to determine the H1/H2 haplotype, with the A-allele tagging H1
and the G-allele tagging H2 (Baker et al., 1999; Cruts et al., 2005;
Rademakers et al., 2005). We have also genotyped variant
rs1800547, with the A-allele tagging H1 and the G-allele tagging
H2 (Baker et al., 1999). With both MAPT variants we obtained the
same results, as expected since they are in linkage disequilibrium
(R2 ¼ 1 and D’ ¼ 1, HapMap 22). Other candidate modiﬁer varia-
tions in TMEM106B, PSAP, SORT1, and C9orf72 were genotyped
using Sanger sequencing on a 3730 DNA Analyzer (Applied Bio-
systems) followed by sequence analysis using SeqMan software
(DNASTAR). PCR ampliﬁcation followed by size separation of
amplicons on the 3730 DNA Analyzer was used to determine the
size of the (G4C2)n repeat in C9orf72. Genotypes were assigned
using the in-house developed TracI genotyping software. In-
dividuals who appeared homozygous for the short (6 units) orTable 1
Characteristics of index patients carrying the GRN founder mutation
Index patient Sex Clinical diagnosis Subtype OA AAD
DR2.1 m FTDc bvFTD 67 71
DR8.1 f FTDa,b bvFTD 62 68
DR25.1 f FTDa,b,c bvFTD 69 75
DR26.1 m FTD PPA (PNFA) 65 68
DR27.1 f FTDa bvFTD 58 63
DR28.1 m FTDa,b PPA (PNFA) 56 62
DR31.1 m FTDa,b PPA (PNFA) 65 70
DR119.1 f FTDa PPA (PNFA) 45 49
DR142.1 f AD 66 73
DR205.1 m PDþDa,b 55 60
DR404.1D f AD PPA (SD) 55 62
DR632.1 f AD 60 69
DR686.1 f FTD unspeciﬁed 61 68
DR792.1 f FTD PPA (PNFA) 69 /
DR985.1 f AD PPA (SD) 57 62
DR1194.1 f FTD PPA (PNFA) 62 /
DR1206.1 f FTD bvFTD 53 59
DR1207.1 f FTDa,b PPA (PNFA) 62 66
DR1208.1 f FTD PPA (PNFA) 63 67
DR1209.1 m FTD PPA (PNFA) 60 64
DR1210.1 m FTD PPA (SD) 70 /
DR1211.1 m FTD bvFTD 56 62
DR1213.1 m FTDa,b bvFTD 58 60
DR1214.1 m FTD bvFTD 54 /
DR1241.1 f FTD bvFTD 72 76
DR1275.1 m FTD bvFTD 54 60
DR1276.1 m AD 54 61
DR1277.1 f PD 76 /
DR1278.1 m PDþD 49 63
Note: For each index patient the sex, clinical diagnosis, and subclass, onset age and
age at death are summarized. Families in which a second mutation in a neurode-
generative brain disease-related gene is present, are indicated with D.
Key: AAD, age at death; AD, Alzheimer’s dementia; bvFTD, behavioral variant of
frontotemporal dementia; OA, onset age; PD, Parkinson’s disease; PDþD, Parkin-
son’s disease with dementia; PNFA, progressive nonﬂuent aphasia; PPA, primary
progressive aphasia; SD, semantic dementia.
a GRN founder (n ¼ 9) patient carriers with autopsy conﬁrmed FTLD-TDP pro-
teinopathy type A (Fig. 3.4), of which.
b 7 brains underwent a detailed neuropathology examination.
c In addition, one relative of index patients DR2.1 and DR25.1, had FTLD-TDP
proteinopathy type A and a detailed neuropathology examination (R.V., personal
communication, 2016; Sieben et al., 2018). .intermediate (7e24 units) G4C2 repeat allele were screened with a
reverse repeat-primed PCR to detect a possible repeat expansion
(Gijselinck et al., 2012).
2.3. Estimation of the effect of risk variations on onset age
Effects of candidate modiﬁer variations on onset age were
estimated using a reversible jump Markov chain Monte Carlo al-
gorithm for censored quantitative traits in Loki (Heath, 1997). In
addition to gender, genotypes or haplotypes of candidate modiﬁer
variations were entered in the trait model as a ﬁxed major gene
covariate to estimate whether a variation can explain the variance
in onset age (Wijsman and Yu, 2004). The founder family was
analyzed as one pedigree, linked together by a common founder.
Genotypes of 79 mutation carriers and 82 family members
without GRN mutation were included in the analysis. Ages of in-
dividuals with the TARDBP p.G287S mutation and of their relatives
DR404 II.1, II.2, and II.3 were excluded from analysis, since we
could not exclude an effect on onset age (Supplementary Fig. S2).
C9orf72 repeat length and APOE genotypes were analyzed as
dichotomous variables. The normal lengths of the G4C2 repeat
were categorized as short (6 repeat units) and intermediate
(7e24 repeat units) alleles (van der Zee et al., 2013). Repeat sizes
>24 units (31 units, unaffected founder mutation carrier of
55 years; 26 units, relative without GRN mutation) were included
as intermediate alleles. For APOE, the ε4 risk allele was analyzed in
comparison to the ε2 plus ε3 alleles. A signiﬁcance threshold of
p<0.05 was used.
2.4. GRN serum levels
Serum GRN levels were measured in duplicate in 1 experiment
by a sandwich enzyme linked-immunosorbent assay (AdipoGen
Life Sciences), according to manufacturers’ instructions. The
average intra-assay coefﬁcient of variability was 4.85%. The indi-
vidual coefﬁcients of variability were deduced from the calculated
concentrations by dividing the standard deviation of the duplicate
measures by the duplicate average and multiplying by 100. Dupli-
cate measurements were averaged for further analysis. Nonpara-
metric Kruskal-Wallis or Mann-Whitney U test was used to
compare levels between mutation carriers and control individuals
and between mutation carriers with different genotypes at risk
variations. Calculations were performed using SPSS version 22.
Correlation between onset age and GRN levels was assessed using a
Cox mixed effects model where kinship was included in the model
to correct for relatedness. Calculations were performed using the R-
packages coxme and kinship2 in R (R Core Team, 2014; Sinnwell
et al., 2014).
2.5. Haplotype sharing analysis
Polymorphic short tandem repeat (STR) markers, located in and
ﬂanking the GRN founder haplotype at 17q21, were PCR-ampliﬁed,
and the products were separated and analyzed on a 3730 DNA
Analyzer (Applied Biosystems) (Brouwers et al., 2007; van der Zee
et al., 2006). Genotypes were assigned using the in-house devel-
oped TracI genotyping software.
2.6. Estimation of shared ancestry
The distance from index patients of the GRN founder family to the
most recent common ancestor was estimated using ESTIAGE soft-
ware (Genin et al., 2004). STRmarker and haplotype data ﬂanking the
GRN mutation were included in the analysis for 13 index patients
with phase-determined haplotypes. The allele frequencies were
E. Wauters et al. / Neurobiology of Aging 67 (2018) 84e94 87determined in unrelated control individuals (n ¼ 102). The recom-
bination fractions were computed using the Kosambi mapping
function.We assumed a stepwise mutationmodel that seems to hold
better for STR loci and a mutation rate of 104 or 103 (Fan and Chu,
2007; Genin et al., 2004). This corresponds to published mutation
rates at STR loci, although these rates can vary greatly (Brinkmann
et al., 1998).Fig. 1. Merged GRN founder pedigree. The 29 branches are illustrated, aligned to 5 generati
founder via a dotted line, indicating that they are not supported by genealogical evidence
patients, the age at last examination for unaffected individuals and the age at death for una
patients; gray symbols, individuals with an unclear affection status; slash, deceased individ3. Results
3.1. Belgian GRN founder family
Since the ﬁrst description of the GRN founder family (Cruts et al.,
2006), the pedigree has been considerably extended. It currently
consists of 29 branches of index patients carrying the GRN founderons based on birth year. The branches are connected to each other and to the common
and separated by an unknown number of generations. The onset age is indicated for
ffected deceased individuals. Circles represent females; squares, males; black symbols,
uals; *, DNA material available.
E. Wauters et al. / Neurobiology of Aging 67 (2018) 84e9488mutation (IVS1þ5 G>C; p.0) and spans at least 5 generations (Fig. 1,
Table 1). DNA is available of 175 family members, including 79
mutation carriers. The mutation so far, has only been identiﬁed in
the Flanders-Belgian population. All carriers share a haplotype
indicating that they are genetically related and belong to 1 founder
pedigree (Supplementary Table S1). The distance to themost recent
common ancestor, carrying the founder mutation, was estimated at
40 generations (95% conﬁdence interval [CI] 27e58, mutation rate
103) by the Estiage program and increased to 46 generations (95%
CI 32e67) when we considered a mutation rate of 104.Table 2
Demographic and clinical characteristics of GRN founder mutation carriers with
clinical diagnosis
Patient characteristics GRN founder mutation
Total, n 43 [38]
Gender, n male (%) 18 (41.9)
Diagnosis, n (%)
FTD 32 (74.4) [28]
AD 6 (14.0) [5]3.2. Phenotypic heterogeneity in GRN founder mutation carriers
3.2.1. Onset age variability
Considering all patients in the pedigree, independent of the
availability of DNA or clinical diagnosis, the onset age ranged from
45 to 80 years with an average of 63.1  7.7 years (n ¼ 79) (Fig. 2).
The disease duration was 6.1  3.8 years (n ¼ 66, range 1e20), and
death occurred at 70.0  7.2 years (n ¼ 72, range 49e85).
3.2.2. Clinical heterogeneity
For 40 of the 79 patients with onset age data, DNA material was
available, and a GRN founder mutation was identiﬁed. Three were
obligate carriers and had a clinical neurodegenerative disease
diagnosis. Of these 43 patients, 32 were diagnosed with FTD (74%,
spread over 21 branches of the pedigree), 6 with AD (14%, in 6
branches), 2 with PD (5%, in 2 branches), 2 with PD and dementia
(PDþD) (5%, in 2 branches), and 1 with dementia unspeciﬁed (2%).
Fifteen FTD patients (in 11 branches) were diagnosed with bvFTD,
14 patients (in 13 branches) with PPA, and 2 patients with a mixed
FTD phenotype (Table 2, Supplementary Table S4).
Detailed clinical information was available for 38 patients.
Thirteen FTD patients were diagnosed with bvFTD, of whom 5 had
predominant symptoms of apathy (39%), 5 of disinhibition (39%), 2
of executive dysfunction (15%), and in 1 the predominant feature
was unclear. Nine of 14 FTD patients with PPA had a nonﬂuent
aphasia (64%), 2 patients had a semantic dementia (14%), and 3
patients had an unclear language subtype. Overall, behavioral and
language symptoms were reported in 27 (71%) and 25 (66%) pa-
tients, respectively. Apathy was the most frequent reported
behavioral feature (67%), and word-ﬁnding difﬁculties were the
most frequent reported language feature (52%). Although only 5
patients were diagnosed with AD, early memory problems were
reported in 17 patients (45%), and early orientation problems in 11
patients (29%). Detailed ﬁndings of clinical neurological examina-
tions were available for 32 patients. In nearly half of them (47%),Fig. 2. Age distribution of GRN founder mutation carriers. For patients, the onset age
and the age at death are indicated, for at-risk individuals, the age at last examination.
(Adapted and extended from [Brouwers et al., 2007]).extrapyramidal symptoms were present. Upper motor neuron
symptoms were present in 11 patients (34%). An overview of the
reported clinical symptoms and signs can be found in
Supplementary Tables S2 and S5.
In 30 of 34 patient carriers, cerebral atrophy was reported. The
atrophy was in most patients predominantly present in the frontal
and/or temporal lobes (80%) and asymmetric in half of the patients
(Fig. 3.1). Parietal atrophy was reported in 24% (6/25), and hippo-
campal atrophy was reported in 20% (5/25). Abnormal ﬁndings on
functional neuroimaging (ﬂuorodeoxyglucose positron emission
tomography or perfusion single-photon emission computed to-
mography) were reported for 22 of 23 patients of whom 13 had
predominant frontal and/or temporal hypometabolism/-perfusion
(Fig. 3.2) and 15 (68%) had additional or isolated parietal lobe
involvement (Fig. 3.3). In 20 patients (91%), the pattern of the
functional abnormalities was reported to be asymmetric
(Supplementary Tables S3 and S6). Dopamine transporter imaging
was performed in 3 of the 4 PD patients and conﬁrmed a presyn-
aptic dopaminergic deﬁcit.3.3. GRN as modiﬁer of onset age
Wemeasured serum GRN levels of 22 founder mutation carriers
from 17 branches (onset age 62.2  9.3 years, range 45e76). The
levels in GRN mutation carriers (median 27.3 ng/mL, range
12.8e39.8 ng/mL) were signiﬁcantly lower (p ¼ 0.0001) in com-
parison to the levels measured in control individuals (median
74.2 ng/mL, range 56.2e90.3 ng/mL) with no overlap between both
groups. There was no evidence of correlation between onset age
and GRN levels (Cox mixed effects p ¼ 0.41).
In the founder family, the major C-allele of rs5848, situated in
the GRN 30UTR, is located on the mutant haplotype. The onset age
of heterozygous rs5848 C/T carriers was on average 3.5 years
earlier compared to C/C carriers (p¼ 0.042, minor allele frequency
[MAF] ¼ 0.23, Table 3). There were no differences in serum GRND 1 (2.3) [1]
PD 2 (4.7) [2]
PD þ D 2 (4.7) [2]
Subtype FTD, n (% within FTD patients
with known subtype)
bvFTD 15 (48.4) [13]
PPA 14 (45.2) [14]
MXD 2 (6.5) [1]
Average OA (n ¼ 43) 61.2  7.3 y
Average DD (n ¼ 33) 5.5  2.2 y
Average AAD (n ¼ 33) 66.4  6.4 y
Familial history, n (%)
F 33 (76.7)
S 7 (16.3)
Note: Numbers between square brackets indicate the number of individuals with
detailed clinical information available.
Key: AAD, age at death; AD, Alzheimer’s dementia; bvFTD, behavioral variant of
frontotemporal dementia; D, dementia unspeciﬁed; DD, disease duration; F, famil-
ial; FTD, frontotemporal dementia; LOF, loss-of-function; MXD, mixed fronto-
temporal dementia (both behavioral and language features without clear
predominance); OA, onset age; PD, Parkinson’s disease; PDþD, Parkinson’s disease
with dementia; PPA, primary progressive aphasia; S, sporadic.
Fig. 3. Distinctive neuroimaging and neuropathological ﬁndings in GRN founder mutation carriers. 3.1 Structural neuroimaging DR1208.1: Coronal MRI T2-weighted image illustrating
asymmetric atrophy, which is in this case more pronounced at the left side. 3.2 Functional neuroimaging DR1208.1: These z-map rendering FDG-PET images, with Z value (scale bar)
calculated by comparing the individual glucose metabolic pattern to the normal age-matched control, illustrate asymmetric predominant left frontal hypometabolism. (A) Anterior
view. (B) Left lateral view. (C) Left medial view. (D) Right medial view. 3.3 Functional neuroimaging DR28.3: These z-map rendering FDG-PET images, with Z value (scale bar)
calculated by comparing the individual glucose metabolic pattern to the normal age-matched control, illustrate asymmetric hypometabolism in the right frontal, temporal, and
parietal lobes. (A) Left lateral view. (B) Right lateral view. (C) Superior view. (D) Inferior view. (E) Anterior view. (F) Posterior view. (G) Left medial view. (H) Right medial view. 3.4
FTLD-TDP type A pathology: Parafﬁn-embedded sections stained with antihyperphosphorylated TDP-43 antibody. (A) DR31.1 Area 6. Moderate amount of neuronal cytoplasmic
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Table 3
Effect of genetic modiﬁer variations on onset age in the GRN founder family
E. Wauters et al. / Neurobiology of Aging 67 (2018) 84e9490levels between mutation carriers with a T- or C-allele on the
normal haplotype (n ¼ 22, p ¼ 0.25).Variation Minor allele MAF Htz vs WT Hmz vs WT
D OA SD p-value D OA SD p-value
GRN rs5848 T 0.23 3.5 2.0 0.042
SORT1 rs611917 C 0.32 2.5 2.1 0.111 1.3 3.6 0.354
SORT1 rs646776 G 0.27 0.6 2.0 0.389 2.9 5.4 0.285
PSAP rs1867977 T 0.36 2.5 2.1 0.113 -2.5 3.0 0.200
PSAP rs7869 T 0.23 3.3 2.3 0.075 -0.7 4.1 0.431
TMEM106 B
rs1990622
C 0.26 2.4 2.0 0.110 1.5 7.4 0.430
C9orf72 G4C2 repeat intermediate 0.27 3.8 2.0 0.035 5.6 5.9 0.173
C9orf72 rs2814707 T 0.31 3.6 2.0 0.038 6.1 5.5 0.133
MAPT H1/H2 H2 0.36 5.9 3.9 0.065 7.8 4.2 0.032
APOE Ɛ4 0.14 0.8 2.6 0.388 7.7 5.6 0.083
p-values < 0.05 are bold italicized.
Key: D OA, difference in onset age in years; Htz, heterozygous; Hmz, homozygous;
MAF, minor allele frequency; SD, standard deviation; WT, wild-type.3.4. Other modiﬁers of onset age
We did not observe a signiﬁcant effect of the SORT1 and PSAP
variants, TMEM106B rs1990622, and APOE ε4 on onset age; neither
did we detect differences in serum GRN levels between patients
carrying different genotypes at SORT1 and PSAP variations. Homo-
zygous carriers of the MAPT H2 haplotype developed disease on
average 7.8 years later than homozygous H1 carriers (p ¼ 0.032,
MAF ¼ 0.36) (Table 3). We also identiﬁed a signiﬁcant effect of the
C9orf72 G4C2 repeat size on onset age. Patients heterozygous for an
intermediate repeat developed disease on average 3.8 years earlier
compared to patients with 2 short alleles (p¼0.035, MAF ¼ 0.27)
(Table 3).4. Discussion
Mutations in GRN are an important cause of FTLD and related
neurodegenerative disorders. The GRN IVS1þ5 G>C null mutation
was originally described in a Belgian founder family, which was
characterized by a wide variability of clinical symptoms and onset
ages of disease (Brouwers et al., 2007; Cruts et al., 2006; van der Zee
et al., 2006). We have extended the Belgian GRN founder pedigree
to 29 branches including 85 patients and 40 unaffected carriers.
This was achieved by recruiting patients and relatives of known
branches and newly identiﬁed index patient carriers and relatives.
Further, all index patients included in our Belgian neurodegenera-
tive brain diseases patient cohort are routinely screened for causal
mutations in genes associated with neurodegenerative brain dis-
eases using parallel sequencing. In this way, we identiﬁed since our
latest report (van der Zee et al., 2011), an additional 19 index car-
riers of the founder mutation, bringing the total to 29 branches, and
biomaterials of 44 individuals including 29 founder mutation car-
riers have been added.
In the founder pedigree, three quarters of the patients of
whom we have a clinical diagnosis available received a clinical
diagnosis of FTD, half bvFTD, and half PPA. Apathy was the most
frequent FTD behavioral feature, and nonﬂuent progressive
aphasia was the most frequent PPA variant. Parkinsonism was
reported in about half of the patients. On neuroimaging, asym-
metric brain damage as well as parietal involvement was
frequently reported. These ﬁndings are consistent with previous
reports (e.g., [Beck et al., 2008; Rohrer et al., 2010; Whitwell et al.,
2009]). Other diagnoses were AD, unspeciﬁed dementia, PD, and
PDþD. Behavioral features were present in 5 and language
symptoms in 3 of the 8 patients with a nonFTD dementia diag-
nosis. In the 5 AD patients, the diagnosis was based on early
episodic memory and/or orientation problems with parietal or
more global involvement on neuroimaging. In one of them, the
CSF biomarker proﬁle was in accordance with AD, while in 3
others, the proﬁle was not typical for AD. The 3 PD patients that
had dopamine transporter imaging performed, had a decreased
striatal uptake. In 1 patient with clinical PDþD (Table 1, DR205.1),=
inclusions (NCI) (arrow), mainly in the second cortical layer. The dystrophic neurites (DN) (
Mild amount of NCI (arrow) in the second cortical layer. (C) DR8.1 Area 4. Similar ﬁndings: mi
Note the presence of one neuronal intranuclear inclusion (arrow head) and different DN
proteinopathy type A with NCI (arrow) and DN (double arrow head). (E) DR25.1 Parietal
head) in the second cortical layer. (F) DR31.1 Area striata. Mild amount of NCI (arrow) and
amount of NCI (arrow) and one neuronal intranuclear inclusion (arrow head) in the subiculum
nucleus caudatus. (I) DR8.1. White matter of the frontal cortex. Presence of glial cytoplasmi
emission tomography; FTLD, frontotemporal lobar degeneration; FTLD-TDP FTLD-TAR DNA-
right; S, superior.characterized by severe frontal dysfunction and early episodic
memory impairment, postmortem neuropathological examina-
tion revealed a combination of FTLD-TDP type A, diffuse Lewy
body pathology, and mild AD-related pathology (Brouwers et al.,
2007). In total, neuropathological examination was performed in
11 founder mutation carriers, all showing FTLD-TDP type A
(Table 1, Fig. 3.4) (R.V., personal communication, 2016; Sieben
et al., 2018). In depth examination of 9 patients revealed
atherosclerotic changes of the small vessels in cortex and white
matter as well as mild AD-related amyloid and/or tau pathology
in all patients (Table 1) (Sieben et al., 2018).
Patients carrying the GRN founder mutation received their
clinical diagnosis in different hospitals and different clinical set-
tings between 1993 and 2014, implicating that the used diagnostic
tools and standards were not in all patients equally advanced. This
implies that some diagnoses might be misdiagnoses due to a lack of
diagnostic tools at the time, such as ﬂuorodeoxyglucose positron
emission tomography or amyloid-PET of the brain or lumbar
puncture to determine biomarker levels in CSF. However, the
frequent combined pathology of FTLD-TDP type Awith Alzheimer’s
and/or synucleinopathy features, suggests that at least a part of the
heterogeneous clinical phenotype of GRN mutation carriers might
be the result of additional pathologies. The question remains why
additional neuropathological features occur frequently in GRN
mutation carriers (Hosokawa et al., 2017; Kelley et al., 2009). Given
the function of GRN as a neurotrophic factor, which enhances
neuronal survival (Van Damme et al., 2008), and the increased
cellular aging that was postulated from the cytological changes
seen in granulin knockout mice (Ahmed et al., 2010; Wils et al.,
2012), it is plausible that GRN haploinsufﬁciency lowers the
threshold for other neurodegenerative pathologies or accelerates
age-related neurodegeneration. Related to this, it is interesting to
note that variations in TMEM106B and GRN have recently been
identiﬁed in a genome-wide association study for differential aging
(Rhinn and Abeliovich, 2017).
We observed in the founder pedigree a wide variability in onset
age, ranging from 45 to 80 years, suggesting the inﬂuence of onset
age modiﬁers. We investigated the effect of previously reporteddouble arrow) are more evenly spread throughout the entire cortex. (B) DR8.1 Area 11.
ld to moderate NCI (arrow) in the second cortical layer. No involvement of Betz neurons.
(double arrow head). (D) DR2.3 Superior temporal gyrus. Mild to moderate TDP-43
cortex. Mild amount of NCI (arrow) and one neuronal intranuclear inclusion (arrow
DN (double arrow head) in the second cortical layer. (G) DR25.1 Hippocampus. Mild
. (H) DR31.1 Neostriatum. Large amount of NCI (arrow) and DN (double arrow head) in
c inclusions (arrow). Abbreviations: A, anterior; FDG-PET, ﬂuorodeoxyglucose positron
binding protein 43;I, inferior; L, left; MRI, magnetic resonance imaging; P, posterior; R,
E. Wauters et al. / Neurobiology of Aging 67 (2018) 84e94 91modiﬁers of onset age or disease risk. For the GRN rs5848 variation,
homozygous carriers of the major C-allele developed symptoms on
average 3.5 years later than heterozygous carriers of the risk T-
allele. The variation is located in the 30UTR within a binding site for
miR-659. This miRNA binds more efﬁciently to the T-allele resulting
in a translational inhibition of GRN (Rademakers et al., 2008). We
did not identify a correlation between serum GRN levels and onset
age, consistent with previous results (e.g., [Meeter et al., 2016;
Sleegers et al., 2009]) but in contrast with the ﬁnding of an
earlier onset in patients with the lowest GRN levels (Ghidoni et al.,
2012). Analysis of the effect of the H1/H2 haplotypes of MAPT,
which is located adjacent to GRN on chromosome 17, indicated that
H2/H2 carriers develop disease on average 7.8 years later than H1/
H1 carriers. Though, caution is needed in interpreting this result,
because only 3 patients were homozygous H1/H1 carriers (onset
ages 49e54 years) due to the location of H2 on the disease haplo-
type in most branches of the founder family. The effect on onset age
is in agreement with the protective effect of H2 in progressive
supranuclear palsy (Baker et al., 1999). Of interest, also in Italian
patients carrying the GRN p.Thr272SerfsX10 mutation, the MAPT
haplotype is an onset age modiﬁer; H2/H2 carriers developed dis-
ease later in comparison to patients with H1/H2 haplotypes
(Benussi et al., 2009). In contrast, other studies in clinical FTD pa-
tients have reported an earlier disease onset in H2 carriers (Borroni
et al., 2005; Laws et al., 2007). Patients of the pedigree heterozy-
gous for an intermediate C9orf72 G4C2 repeat allele, developed
disease on average 3.8 years earlier than patients with two short
normal alleles. We could not detect a signiﬁcantly lower onset age
in carriers of two intermediate alleles, since there were only very
few homozygous carriers of intermediate alleles, i.e. one patient
with onset age 70 years and two asymptomatic GRN mutation
carriers aged 34 and 48 years. No onset age-modifying effects were
observed for the genetic variations in the SORT1 and PSAP loci. We
could not replicate a signiﬁcant difference in serum GRN levels
between patients with different genotypes (Carrasquillo et al.,
2010; Nicholson et al., 2016), but we cannot exclude that the low
number of samples limited the detection of subtle differences in
GRN levels. Consistent with our earlier results, no signiﬁcant onset
age-modifying effect of TMEM106B rs1990622 or APOE ε4 was
observed (Cruts et al., 2006; van der Zee et al., 2011). Although we
did not see an onset age modifying effect of the rs1990622 varia-
tion, we did notice that none of the affected mutation carriers was
homozygous carrier of the protective C-allele, supporting a pro-
tective effect of TMEM106B rs1990622. Variations in TMEM106B
have been identiﬁed as a risk factor for FTLD-TDP, with the greatest
effect in GRN mutation carriers (Van Deerlin et al., 2010). Further-
more, an effect on onset age has been observed in GRN mutation
carriers (Cruchaga et al., 2011).
For the loci we investigated, positive as well as negative asso-
ciations with disease or onset age have been reported indicating
that studies in larger cohorts will be needed to obtain solid results
(e.g.,[Rademakers et al., 2008; Rollinson et al., 2011; Rubino et al.,
2013; Van Deerlin et al., 2010; van der Zee et al., 2011]). It is
possible that small effects were detected in some families or co-
horts, while in other groups of patients, the effect did not reach
statistical signiﬁcance. Also in our study, effect sizes were small and
would not reach statistical signiﬁcance in a genome-wide study of
modiﬁer variations. GRN, MAPT, and C9orf72 repeat length
explained 2.7%, 4.4%, and 5.6% of the variability in onset age in the
pedigree, indicating the involvement of other modifying factors.
One possibility is that pathogenic mutations in other causal genes
associated with neurodegenerative brain diseases could exert a
modifying effect. In one branch of the pedigree, we identiﬁed the
p.G287S mutation in TARDBP (Supplementary Fig. S2), a well-
established causal gene for amyotrophic lateral sclerosis (Kabashiet al., 2008; Sreedharan et al., 2008). Rare TARDBP mutation car-
riers have also been identiﬁed, who present clinically with FTD
(Borroni et al., 2010). Since only 1 nonaffected individual carrying
both the GRN founder mutation and the TARDBP mutation was
identiﬁed in the founder family, we cannot make a ﬁrm statement
about the potential of a modifying effect on disease presentation.
The phenotypic heterogeneity in patients carrying the same GRN
mutation, emphasizes that neurodegenerative brain diseases are
rather a continuum of disorders, overlapping in genetics, patho-
logical features, and clinical phenotypes. Appreciating the disease
heterogeneity associated with loss-of-function mutations in GRN is
of major importance for genetic counseling.Within families, clinical
heterogeneity could mask the presence of an underlying genetic
defect segregating with neurodegenerative disease. Furthermore,
the phenotype of a GRN mutation carrier cannot be predicted by
phenotypical characteristics of relatives. Heterogeneity within
families points toward the presence of disease modiﬁers. Within
the founder family, GRN rs5848, MAPT H1/H2 haplotype, and
C9orf72 G4C2 repeat length were identiﬁed as putative genetic
modiﬁers of onset age, though their effect size was limited. This
implies that other modifying factors still need to be identiﬁed in
this family, for example, by using exome- or genome-wide ap-
proaches. Identifying those novel factors is of great signiﬁcance
since they could be targets for disease-modifying therapies, which
are currently not available for FTD patients.
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